On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in ...

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...

We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a ...

Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...

Former government health officials fear the Trump administration is moving to slow-walk vaccine approvals, including by ...

Moderna, the bloodied Covid-era prizefighter of the healthcare sector, stumbles toward its next earnings report on Thursday ...

Novavax faces uncertainty as FDA requests a new clinical trial for its COVID-19 vaccine, the last protein-based option in the ...

As the world marks World Immunization Week, attention turns once again to the lifesaving power of vaccines.Amid headlines about rising cases of measles, falling vaccination rates and growing vaccine ...

Moderna is currently in the very early stages of testing a bird flu vaccine using the same mRNA technology that allowed for rapid development and rollout of COVID-19 vaccines. The funds from the ...